Bruton's tyrosine kinase inhibitors

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in comb...

Full description

Saved in:
Bibliographic Details
Main Authors Xing, Li, Schnute, Mark Edward, Hughes, Robert Owen, Walker, Daniel Patrick, Devadas, Balekudru, Selness, Shaun Raj, Zapf, Christoph Wolfgang, Wan, Zhao-Kui, Springer, John Robert, Garland, Danny James, Schmidt, Michelle Ann, Han, Seungil, Hockerman, Susan Landis, Grapperhaus, Margaret Lanahan, Saiah, Eddine
Format Patent
LanguageEnglish
Published 27.10.2020
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Bibliography:Application Number: US201916296319